Skip to search formSkip to main contentSkip to account menu

MAC321

Known as: MAC 321, MAC-321 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Paclitaxel

Narrower (2)

TL 139milataxel
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Overcoming extractability hurdles of a 14C labeled taxane analogue milataxel and its metabolite from xenograft mouse tumor and brain tissues.
2007
2007
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors
PurposeMAC-321 is a novel taxane that has demonstrated exceptional activity in human xenograft models when administered… 
2006
2006
A phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy.
7098 Background: M (TL139, MAC-321) is a novel taxane that has shown activity when administered IV or orally in both taxane… 
2006
2006
Phase I trial of glycolitic inhibition with 2-deoxyglucose and docetaxel for patients with solid tumors
515 Background: The slow growing cell population of solid tumors that is associated with hypoxia presents a formidable mode of… 
2006
2006
Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors.
2037 Background: M (TL139, MAC-321) is a novel taxane with activity in human xenograft models against tumors resistant to… 
2004
2004
Phase 1 trial of oral MAC-321 in subjects with advanced malignant solid tumors.
2040 Background: MAC-321 is a novel taxane that has demonstrated exceptional activity in human xenograft models when administered… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)